



HEB

Journal of Hospital Pharmacy
 An Official Publication of Bureau for Health & Education Status Upliftment
 (Constitutionally Entitled A)

JOHP

HIV Drug Development : Novel Approach

Supriti Padhan*¹, Dr.B.Ray¹, Dr.C.K.Sahoo²

*^{1,1}Dept.of Pharmacology,Gayatri college of Pharmacy,Sambalpur


²Dept.of pediatric,SCBMCH,Cuttack

Email Id: editorjohp@gmail.com

ABSTRACT

Untreated HIV infection is characterized by a gradual deterioration of immune function. Most notably, crucial immune cells known as CD4 positive T lymphocytes are disabled and killed during the typical course of infection. These T lymphocyte cells play a central role in the immune response. The study of HIV structure, genome and its life cycle has revealed many exciting target sites for acquired immunodeficiency syndrome treatment. Many conventional treatments for acquired immunodeficiency syndrome are merely capable of prolonging the patient's life but are unable to completely eradicate the virus as the virus mutates rapidly and develops resistance. So there are many recent novel approaches under consideration like integrase inhibitor, fusion inhibitor and ribozymes for the treatment of acquired immunodeficiency syndrome. Now approaches by CADD are progressively effective to develop a new molecule which can modify the therapeutic approach with a minimal adverse effect.

Key word : Immunodeficiency syndrome, Glycoprotein, RNA polymerase, Integrase, protease.

Access this Article Online	Quick Response Code: 
Website: http://www.journalofhospitalpharmacy.in	
Received on 05/10/2020	
Accepted on 01/11/2020 © HEB All rights reserved	